Review of sertraline in post-traumatic stress disorder

REFERENCES

• American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders — IV. (1994) American Psychiatric Association, Washington DC, USA
   Google Scholar
• KESSLER RC, SONNEGA A, BROMET E, HUGHES M, NELSON CB: Posttraumatic stress disorder in the National Comorbidity Survey. Arch. Gen. Psychiatry (1995) 52:1048–1060.
   PubMed Web of Science ®Google Scholar
• BRESLAU N, DAVIS GC, ANDRESKI MA, PETERSON E: Traumatic events and posttraumatic stress disorder in an urban population of young adults. Arch. Gen. Psychiatry (1991) 48:216–222.
   PubMed Web of Science ®Google Scholar
• RESNICK HS, KILPATRICK DG, DANSKY BS, SAUNDERS BE, BEST CL: Prevalence of civilian trauma and posttraumatic stress disorder in a representative national sample of women. j. Consul. Clin. Psychology(1993) 61:984–991.
   PubMed Web of Science ®Google Scholar
• DAVIDSON JR, HUGHES D, BLAZER DG, GEORGE LK: Post-traumatic stress disorder in the community: an epidemiological study. Psychological Medicine (1991) 21(3):713–721.
   PubMed Web of Science ®Google Scholar
• SOLOMON SD, DAVIDSON JR: Trauma: prevalence, impairment, service use, and cost. J. Clin. Psychiatry (1997) 58 (Suppl. 9):5–11.
   Google Scholar
• NORRIS FH: Epidemiology of trauma: frequency and impact of different potentially traumatic events on different demographic groups. I Consult. Clin. Psychology (1993) 61:984–991.
   PubMedGoogle Scholar
• BRADY K, PEARLSTEIN T, ASNIS GM et al.: Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA (2000) 283:1837–1844.
   PubMed Web of Science ®Google Scholar
• ••Pivotal 12-week, multi-centre, placebo-controlled, randomised trial of sertraline for patients with a diagnosis of PTSD.
   Google Scholar
• MCFARLANE AC, ATCHISON M, RAFALOWICZ E, PAPAY P: Physical symptoms in post-traumatic stress disorder. Psychosom. Res. (1994) 38(7):715–726.
   PubMed Web of Science ®Google Scholar
• CORDOVA MJ, ANDRYKOWSKI MA, KENADY DE, MCGRATH PC, SLOAN DA, REDD WH: Frequency and correlates of posttraumatic-stress-disorder-like symptoms after treatment for breast cancer. Consult. Clin. Psychology (1995) 63(6):981–986.
   PubMed Web of Science ®Google Scholar
• FERRADA-NOLI M, ASBERG M, ORMSTAD K, LUNDIN T, SUNDBOM E: Suicidal behavior after severe trauma. Part 1: PTSD diagnoses, psychiatric comorbidity, and assessments of suicidal behavior. J. Trauma Stress (1998) 11(1):103–112.
   Google Scholar
• WENNINGER K, HEIMAN JR: Relating body image to psychological and sexual functioning in child sexual abuse survivors. .1. Trauma Stress (1998) 11(3):543–562.
   Google Scholar
• RIGGS DS, BYRNE CA, WEATHERS FW, LITZ BT: The quality of the intimate relationships of male Vietnam veterans: problems associated with posttraumatic stress disorder. J. Trauma Strays (1998) 11(1):87–101.
   PubMed Web of Science ®Google Scholar
• BECKHAM JC, LYTLE BL, FELDMAN ME: Caregiver burden in partners of Vietnam War veterans with posttraumatic stress disorder. I Consult. Clin. Psychology (1996) 64(5):1068–1072.
   PubMedGoogle Scholar
• ROTHBAUM BO, MARSHALL R, FOA EB, LINDY J, MELLMAN L: Posttraumatic stress disorder. In: Treatment of Psychiatric Disorders: Third Edition. Gabbard GO (Ed.), American Psychiatric Press, Inc., Washington DC, USA (2001):1539–1566.
   Google Scholar
• CHARNEY DS, DEUTCH AY, KRYSTAL JH, SOUTH WICK SM, DAVIS M: Psychobiologic mechanisms of posttraumatic stress disorder. Arch. Gen. Merl (1993) 50(4):294–305.
   Web of Science ®Google Scholar
• YEHUDA R: Psychoneuroendocrinology of post-traumatic stress disorder. Psychiatr. Clin. North Am. (1998) 21(2):359–379.
   PubMedGoogle Scholar
• BRAUN P, GREENBER D, DASBERG H, LERER B: Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. Clin. Psychiatry (1990) 51:236–238.
   PubMed Web of Science ®Google Scholar
• FORSTER PL, SCHOENFELD FB, MARMAR CR, LANG AJ: Lithium for irritability in post-traumatic stress disorder. .1. Trauma Stress (1995) 8:143–149.
   PubMed Web of Science ®Google Scholar
• LIPPER S, DAVIDSON JR, GRADY TA et al.: Preliminary study of carbamazepine in post-traumatic stress disorder. Psychosomatics (1986) 27:849–854.
   PubMed Web of Science ®Google Scholar
• FORD N: The use of anticonvulsants in posttraumatic stress disorder: case study and overview. J. Trauma Stress (1996) 9:857–863.
   PubMed Web of Science ®Google Scholar
• FESLER FA: Valproate in combat-related posttraumatic stress disorder. J Clin. Psychiatry (1991) 52:361–364.
   PubMed Web of Science ®Google Scholar
• MARSHALL RD, PIERCE D: Implications of recent findings in posttraumatic stress disorder and the role of pharmacotherapy. Harvard Rev. Psychiatry(2000) 7:247–256.
   PubMedGoogle Scholar
• HUDSON JI, POPE HG JR.: Affective spectrum disorder: does antidepressant response identify a family of disorders with a common pathophysiology? Am. J. Psychiatry (1990) 147(5):552–564.
   Google Scholar
• DAVIDSON J, KUDLER H, SMITH R et al.: Treatment of post-traumatic stress disorder with amitriptyline and placebo. Arch. Gen. Psychiatry (1990) 47:259–266.
   PubMed Web of Science ®Google Scholar
• FRANK JB, KOSTEN TR, GILLER EF JR, DAN E: A randomized clinical trial of phenelzine and imipramine for posttraumatic stress disorder. Am. J. Psychiatry (1988) 145:1289–1291.
   PubMed Web of Science ®Google Scholar
• KOSTEN TR, FRANK JB, DAN E, MCDOUGLE CJ, GILLER EL JR: Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. Nerv. Mem. Dis. (1991) 179:366–370.
   PubMed Web of Science ®Google Scholar
• REIST C, KAUFFMANN CD, HAIER RJ et al.: A controlled trial of desipramine in 18 men with posttraumatic stress disorder. Am. Psychiatry(1989) 146(4):513–516.
   PubMed Web of Science ®Google Scholar
• DAVIDSON JR, KUDLER HS, SAUNDERS WB et al.: Predicting response to amitriptyline in posttraumatic stress disorder. Am. J. Psychiatry(1993) 150(7):1024–1029.
   PubMed Web of Science ®Google Scholar
• SHESTATSKY M, GREENBERG D, LERER B: A controlled trial of phenelzine in posttraumatic stress disorder. Psychiatry Res. (1988) 24(2):149–155.
   PubMedGoogle Scholar
• BAKER DG, DIAMOND BY, GILLETE G, HAMMER M: A double-blind, randomized, placebo-controlled, multi-center study of brofaromine in the treatment of posttraumatic stress disorder. Psychopharmacol (1995) 122:386–389.
   PubMed Web of Science ®Google Scholar
• KATZ RJ, LOTT MH, ARBUS P et al.: Pharmacotherapy of post-traumatic stress disorder with a novel psychotropic. Anxiety (1994–5) 1:169–174.
   Google Scholar
• NEAL LA, SHAPLAND W, FOX C: An open trial of moclobemide in the treatment of post-traumatic stress disorder. Int. Clin. Psychopharmacol (1997) 12:231–237.
   PubMed Web of Science ®Google Scholar
• FINLEY PR: Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions. Ann. Pharmacother. (1994) 28:1359–1369.
   PubMed Web of Science ®Google Scholar
• MCRAE AL, BRADY KT: Review of sertraline and its clinical applications in psychiatric disorders. Expert Opin. Pharmacother. (2001) 2(5):883–892.
   PubMedGoogle Scholar
• DAVIS LL, ENGLISH BA, AMBROSE SM, PETTY F: Pharmacotherapy for posttraumatic stress disorder: a comprehensive review. Expert Opin. Pharmacother. (2001) 2(10):1583–1595.
   PubMedGoogle Scholar
• Zoloft Package Insert (USA) Pfizer, Inc. 2002.
   Google Scholar
• HIEMKE C, HARTTER S: Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Titer: (2000) 85:11–28.
   PubMed Web of Science ®Google Scholar
• HYMAN SE, ARANA GW, ROSENBAUM JF: Antidepressant Drugs. In: Handbook of Psychiatric Drug Therapy Third Edition. Little, Brown and Company. New York, NY, US (1995):43–92.
   Google Scholar
• REIMHERR FW, CHOUINARD G, COHN CK et al: Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. I Clin. Psychiatry (1990) 51(Suppl. B):18–27.
   Google Scholar
• PRESKORN SH: Clinically relevant pharmacology of selective serotonin reuptake inhibitors: An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin. Pharmacokinet. (1997) 32\(Suppl. 1):1–21.
   Google Scholar
• RICHELSON E: Phannacoldnetic drug interactions of new antidepressants: A review of the effects of the metabolism of other drugs. Mayo Clin. Proc (1997) 72(9):835–847.
   PubMed Web of Science ®Google Scholar
• FULLER RW: Basic advances in serotonin pharmacology. I Clin. Psychiatry (1992) 53\(Suppl. 10):36–45.
   Google Scholar
• GRIMSLEY SR, JANN MW: Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Clin. Pharm. (1992) 11:930–957.
   PubMedGoogle Scholar
• BOLDEN-WATSON C, RICHELSON E: Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Se/. (1993) 52:1023–1029.
   PubMed Web of Science ®Google Scholar
• MACQUEEN G, BORN L, STEINER M: The selective serotonin reuptake inhibitor sertraline: It's profile and use in psychiatric disorders. CNS Drug Rev (2001) 7(1):1–24.
   PubMedGoogle Scholar
• TOLLEFSON GD: Selective serotonin reuptake inhibitors. In: Textbook of Psychopharmacology Schatzberg AF & Nemeroff CB (Eds), American Psychiatric Press, Inc., Washington DC, USA (1995):161–182.
   Google Scholar
• WARRINGTON SJ: Clinical implications of the pharmacology of serotonin reuptake inhibitors. Int. Clin. Psychopharmacol (1992) 7\(Suppl. 2) (12):13-19.
   Google Scholar
• RUDORFER MV, POTTER WZ: The role
   Google Scholar
• •• of metabolites of antidepressants in the treatment of depression. CNS Drugs (1997) 7(4):273–312.
   Google Scholar
• LEVINE B, JENKINS AJ, SMIALEK JE: Distribution of sertraline in postmortem cases. Anal. Toxicol (1994) 18:272–274.
   PubMed Web of Science ®Google Scholar
• RONFELD RA, WILNER KD, BARIS BA: Sertraline. Chronopharmacokinetics and the effect of co-administration with food. Clin. Pharmacokinet. (1997) 32 (Suppl. 1):50–55.
   Google Scholar
• DEVANE CL: Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. Cell. MM. Neurobiol (1999) 19(4):443–466.
   PubMedGoogle Scholar
• SCHWENK MH, VERGA MA, WAGNER JD: Hemodialyzability of sertraline. Clin. Nephrol. (1995) 44:121–124.
   PubMedGoogle Scholar
• VAN HARTEN J: Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin. Pharacokinet. (1993) 24(3):203–220.
   PubMed Web of Science ®Google Scholar
• LANE RM: Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Lit. Gin. Psychopharmacol (1996) 11(5):31–59.
   PubMedGoogle Scholar
• MARTENYI F, BROWN EB, ZHANG H, PRAKASH A, KOKE SC: Fluoxetine versus placebo in posttraumatic stress disorder. j. Clin. Psychiatry(2002) 63(3):199–206.
   PubMed Web of Science ®Google Scholar
• CONNOR KM, SUTHERLAND SM, TUPLER LA, MALIK ML, DAVIDSON JR: Fluoxetine in post-traumatic stress disorder. Randomised, double-blind study. Br.Psychiatry (1999) 175:17–22.
   PubMed Web of Science ®Google Scholar
• MALIK ML, CONNOR KM, SUTHERLAND SM, SMITH RD, DAVISON RIVI, DAVIDSON JR: Quality of life and posttraumatic stress disorder: a pilot study assessing changes in SF-36 scores before and after treatment in a placebo-controlled trial of fluoxetine. Trauma Stress (1999) 12(2):387–393.
   PubMedGoogle Scholar
• VAN DER KOLK BA, DREYFUSS D, MICHAELS M et al.: Fluoxetine in posttraumatic stress disorder. I Clin. Psychiatry (1994) 55(12):517–522.
   Google Scholar
• TUCKER P, ZANINELLI R, YEHUDA R, RUGGIERO L, DILLINGHAM K, PITTS CD: Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. Clin. Psychiatry(2001) 62(11):860–868.
   PubMed Web of Science ®Google Scholar
• MARSHALL RD, BEEBE KL, OLDHAM M, ZANINELLI R: The efficacy and safety of paroxetine for adults with chronic PTSD: A fixed dose, multi-center, placebo-controlled study. Am. I Psychiatry(2001) 158(12):1982–1988.
   PubMed Web of Science ®Google Scholar
• DAVIDSON JR, ROTHBAUM BO, VAN DER KOLK BA, SIKES CR, FARFEL G: Multi-center, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch. Gen. Psychiatry(2001) 58(5):485–492.
   PubMed Web of Science ®Google Scholar
• •Multi-site, 12-week, double-blind, flexible dose study of outpatients with PTSD comparing sertraline to placebo in adults with moderate-to-severe chronic PTSD.
   Google Scholar
• ROTHBAUM BO, DAVIDSON JR, VAN DER KOLK B, BRADY KT, SIKES C, FARFEL G: Double-blind comparison of sertraline and placebo in patients with posttraumatic stress disorder. International Society for Traumatic Stress Studies (November 1998) Washington, DC, USA.
   Google Scholar
• RAPAPORT MH, ENDICOTT J, CLARY CM: Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. I Clin. Psychiatry (2002) 63(1):59–65.
   PubMedGoogle Scholar
• BRADY KT, SONNE SC, ROBERTS JM: Sertraline treatment of comorbid posttraumatic stress disorder and alcohol dependence. I Gin. Psychiatry (1995) 56(11):502–505.
   Google Scholar
• KLINE NA, DOW BM, BROWN SA, MATLOFF JL: Sertraline efficacy in depressed combat veterans with posttraumatic stress disorder. Presented at the 146th Annual Meeting, American Psychiatric Association (May 1993) San Francisco, CA., USA.
   Google Scholar
• ROTHBAUM BO, NINAN PT, THOMAS L: Sertraline in the treatment of rape victims with Posttraumatic Stress Disorder.' Trauma Stress (1997) 9: 879–885.
   Google Scholar
• BRADY K, AUSTIN C: Affective and anxiety comorbidity in PTSD treatment trials of sertraline [poster] (Eng). 7th European Conference on Traumatic Strays (ESTSS) (May 26–29, 2001) Edinburgh, Scotland.
   Google Scholar
• Physician's Desk Reference (PDR, 2001).
   Google Scholar
• ZOHARJ, AMITAL D, MIODOWNIK C et al: Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. I Clin. Psychopharmacol. (2002) 22(2) :190–195.
   Google Scholar
• LONDBORG PD, HEGEL MT, GOLDSTEIN S et al: Sertraline treatment of posttraumatic stress disorder: results of 24 weeks of open-label continuation treatment. I Gin. Psychiatry (2001) 62:325–331.
   Google Scholar
• •Showing over one-half of acute non-responders converted to responder status with continued medication.
   Google Scholar
• DAVIDSON J, PEARLSTEIN T, LONDBORG P et al.: Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: Results of a 28-week double-blind, placebo-controlled study. Am. I Psychiatry (2001) 158:1974–1981.
   PubMed Web of Science ®Google Scholar
• ••The only long-term study of treatment inPTSD, showing that continued treatment with sertraline yielded lower PTSD relapse rates as compared to placebo.
   Google Scholar
• NELSON JC: Safety and tolerability of the new antidepressants. Gin. Psychiatry (1997) 58:26–31.
   Google Scholar
• HADDAD P: Newer antidepressants and the discontinuation syndrome. Psychiatry (1997) 58:17–22.
   Google Scholar
• HADDAD P: The SSRI discontinuation syndrome. Psychopharmacol (1998) 12:305–313.
   Google Scholar
• HADDAD P: Antidepressant Discontinuation Syndromes. Drug Sal (2001) 24:183–197.
   PubMed Web of Science ®Google Scholar
• FAVA GA, GRANDI S: Withdrawal syndromes after paroxetine and sertraline discontinuation. Clin. Psychopharmacol (1995) 15(5):374–375.
   PubMed Web of Science ®Google Scholar
• FROST L, LAL S: Shock-like sensations after discontinuation of selective serotonin reuptake inhibitors. Am. J Psychiatry(1995) 152:810.
   PubMedGoogle Scholar
• LEITER FL, NIERENBERG AA, SANDERS KM, STERN TA: Discontinuation reactions following sertraline. Biol. Psychiatry (1995) 38:694–695.
   PubMedGoogle Scholar
• LOUIE AK, LANNON RA, AJARI LJ: Withdrawal reaction after sertraline discontinuation. Am. I Psychiatry (1994) 151:450–451.
   PubMedGoogle Scholar
• GOLDBERG RJ: Selective serotonin reuptake inhibitors: Infrequent medical adverse effects. Arch. Fam. Med (1998) 7:78–84.
   PubMedGoogle Scholar
• JACKSON C, CARSON W, MARKOWITZ J, MINTZER J: SIADH associated with fluoxetine and sertraline therapy. Am. I Psychiatry (1995) 152:809–810.
   PubMed Web of Science ®Google Scholar
• CREWS JR, POTTS NL, SCHREIBER J,LIPPER S: Hyponatremia in a patient treated with sertraline. Am. j Psychiatry (1993) 150:1564.
   PubMedGoogle Scholar
• THORNTON S, RESCH D: SIADH associated with sertraline therapy. Am." Psychiatry(1995) 152:809.
   PubMed Web of Science ®Google Scholar
• LLORENTE M, GORELICK M, SILVERMAN M: Sertraline as the cause of inappropriate antidiuretic hormone secretion.j Clin. Psychiatry (1994) 22:543–544.
   Google Scholar
• LIU BA, MITTMANN N, KNOWLES SR, SHEAR NH: Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: A review of spontaneous reports. CMAJ(1996) 155:519–527.
   PubMed Web of Science ®Google Scholar
• BRADLEY ME, FOOTE EF, LEE EN, MERKLE L: Sertraline-associated syndrome of inappropriate antidiuretic hormone: Case report and reviews of the literature. Pharmacotherapy (1996) 16:680–683.
   PubMed Web of Science ®Google Scholar
• CATALANO G, KANFER SN, CATALANO MC, ALBERTS VA: The role of sertraline in a patient with recurrent hyponatremia. Gen. Hosp. Psychiatry (1996) 18:278–283.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN L, BARKER M, SEGALL F, et al.: Seizure and transient SIADH associated with sertraline. Am. j Psychiatry (1996) 153:732.
   Google Scholar
• LOWENTHAL MN: Sertraline-induced hyponatremia in an older patient." Am. Geriatr. So c (1999) 47(10):1274.
   Google Scholar
• RAPHAEL K, TOKESHI J: Hyponatremia associated with sertraline and fluoxetine: A case report. Hawaii Medical Journal (2002) 61(3):46–47.
   PubMedGoogle Scholar
• CHOO V: Paroxetine and extrapyramidal reactions. Lancet (1993) 341:624.
   PubMed Web of Science ®Google Scholar
• SACHDEV P: The identification and management of drug-induced akathisia. Drugs (1995) 4:28–46.
   Google Scholar
• GOLDSTEIN BJ, GOODNICK PJ: Selective serotonin reuptake inhibitors in the treatment of affective disorders-III. Tolerability, safety and pharmoeconomics. J Psychopharmocal (1998) 12(3 Suppl. B):555–587.
   Google Scholar
• ALTSHULER LL, PIERRE JM, WIRSHING WC, AMES D.: Setraline and akathisia. I Clin. Psychopharmacol (1994) 14:278–279.
   Google Scholar
• LAPORTA L: Sertraline-induced akathisia. Clin. Psychopharmacol (1993) 13:219–220.
   PubMed Web of Science ®Google Scholar
• SETTLE E: Akathisia and sertraline. Clin. Psychiatry (1993) 54:321.
   PubMed Web of Science ®Google Scholar
• MENDEL J: Clinical experience with serotonin reuptake inhibiting antidepressants. I Clin. Psychiatry (1987) 48:26–30.
   Google Scholar
• CALHOUN JW, CALHOUN DD: Prolonged bleeding time in a patient treated with sertraline. Am. J. Psychiatry (1996) 153(3):443.
   PubMed Web of Science ®Google Scholar
• YARYURA-TOBIAS JA, KIRSCHEN H, NINAN P, MOSBERG HJ: Fluoxetine and bleeding in obsessive-compulsive disorder. Am. J. Psychiatry(1991) 148:949.
   PubMed Web of Science ®Google Scholar
• ARANTH J, LINDBERG C: Bleeding, a side effect of fluoxetine. Am. J. Psychiatry (1992) 149:412.
   PubMed Web of Science ®Google Scholar
• GUNZBERGER DW, MARTINEZ D: Adverse vascular effects associated with fluoxetine. Arm J. Psychiatry (1992) 149:1751.
   PubMed Web of Science ®Google Scholar
• OTTERVANGER JP, STRICKER BHCH, HULS J, WEEDA JN: Bleeding attributed to the intake of paroxetine. Am. I Psychiatry (1994) 151:781–782.
   PubMed Web of Science ®Google Scholar
• VANDEL P, VANDEL S, KANTELIP JP SSRI-induced bleeding: two case reports. Therapie (2001) 56(4):445–447.
   PubMedGoogle Scholar
• STAHL S: Platelets as pharmacologic models for the receptors and biochemistry of monoaminergic neurons in the platelets. In: Longnecker GL, ed. Physiology and Pharmacology Orlando, FL: Academic Press (1985)307–340.
   Google Scholar
• FISCH C & KNOEBEL SB: Electrocardiographic findings in sertraline depression trials. Drug Invest. (1992) 4:305–312.
   Google Scholar
• SUNDERJI R, PRESS N, AMIN H, GIN K: Unstable angina associated with sertraline. Can.! CardioL (1997) 13:849–851.
   PubMedGoogle Scholar
• BERTI CA & DOOGAN DP: Sudden chest pain with sertraline. Lancet (1994) 343:1510–1511.
   PubMedGoogle Scholar
• IRUELA LM: Sudden chest pain with sertraline. Lancet (1994) 343:1106.
   PubMedGoogle Scholar
• SHELINE YI, FREEDLAND KE, CARNEY RIVI: How safe are serotonin reuptake inhibitors for depression in patients with coronary artery disease. Am. J. Med. (1997) 102:54–59.
   PubMedGoogle Scholar
• SHAPIRO PA, LESPERANCE F, FRASURE-SMITH N et al.: An open-label preliminary of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT trials). Sertraline anti-depressant heart attack trial. Am. Heart J. (1999) 137:1100–1106.
   Google Scholar
• NAIR GV, GURBEL PA, O'CONNOR CM, GATTIS, WA, MURUGESAN SR, SEREBRUANY VL: Depression, coronary events, platelet inhibition, and serotonin reuptake inhibitors. Am. J. Cardiol (1999) 84(3):321–323.
   PubMedGoogle Scholar
• MCFARLANE A, KAMATH MV, FALLEN EL, MALCOLM V, CHERIAN F, NORMAN G: Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. Am. Heart J. (2001) 142(4):617–623.
   PubMed Web of Science ®Google Scholar
• MUSSELMAN DL, MARZEE UM, MANATUNGA A et al.: Platelet reactivity in depressed patients treated with paroxetine: preliminary findings. Arch. Gen. Psychiatry (2000) 57(9):875–882.
   PubMed Web of Science ®Google Scholar
• STERNBACH H: The serotonin syndrome. Arn. J. Psychiatry (1991) 148:705–713.
   PubMed Web of Science ®Google Scholar
• OATES JA, SJOERDSMA A: Neurologic effects of tryptophan in patients receiving a monoamine wddase inhibitor. Neurology (1960) 10:1076–1078.
   PubMed Web of Science ®Google Scholar
• NIERENBERG DW, SEMPREBON M. The central nervous system serotonin syndrome. Clin. Pharmacol Their (1993) 53:84–88.
   PubMedGoogle Scholar
• NEMEROFF CB, DEVANE L, POLLOCK BG: Newer antidepressants and the Cytochrome P450 System. Am. Psychiatry (1996) 153:311–320.
   PubMed Web of Science ®Google Scholar
• PERRY CM, BENFIELD P: Sertraline. An overview of its pharmacological properties and a review of its therapeutic efficacy in obsessive-compulsive disorder. CNS Drugs (1997) 7:480–500.
   Google Scholar
• OZDEMIR V, NARANJO CA, HERRMANN N et al: The extent and determinants of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline. I Clin. Psychopharmacol (1998) 18:55–61.
   Google Scholar
• SPROULE BA, OTTON SV, CHEUNG SW, ZHONG XH, ROMACH MK, SELLERS EM: CYP2D6 inhibition in patients treated with sertraline. I Clin. Psychopharmacol (1997) 17:102–106
   Google Scholar
• ALDERMAN J, PRESKORN SH, GREENBLATT DJ et al.: Desipramine pharmacokinetics when co-administered with paroxetine or sertraline in extensive metabolizers. I Clin. Psychopharmacol (1997) 17:284–291.
   Google Scholar
• KURTZ DL, BERGSTROM RE GOLDBERG MJ, CERIMELE BJ: The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clin. Pharmacol Ther. (1997) 62:145–156.
   PubMed Web of Science ®Google Scholar
• PRESKORN SH, ALDERMAN J, CHUNG M, HARRISON W, MESSIG M, HARRIS S: Pharmacokinetics of desipramine co-administered with sertraline or fluoxetine. Clin. Psychopharmacol (1994) 14:90–98.
   PubMed Web of Science ®Google Scholar
• ZUSSMAN BD, DAVIS CC, FOWLES SE et al.: Sertraline, like other SSRIs, is a significant inhibitor of desipramine metabolism M vivo. Br. J. Clin. Pharmacol (1995) 39:550P–551P
   Google Scholar
• SOLAI LK, MULSANT BH, POLLOCK BG et al.: Effect of sertraline on plasma nortriptyline levels in depressed elderly. Gin. Psychiatry (1997) 58:440–443.
   Google Scholar
• PRESKORN SH: Debate resolved: there are differential effects of serotonin selective reuptake inhibitors on cytochrome P450 enzymes. Psychopharmacol (1998) 12(Suppl. B):589–597.
   Google Scholar
• GOODNICK PJ & GOLDSTEIN BJ: Selective serotonin reuptake inhibitors in affective disorders - I. Basic pharmacology. Psychopharmacol (1998) 12(Suppl. B):55–S20.
   Google Scholar
• APSELOFF G, WILNER KD, GERBER N, TREMAINE LM: Effect of sertraline on protein binding of warfarin. Clin. Pharmacokinetics (1997) 32\(Suppl. 1):37–42.
   Google Scholar
• RAPEPORT WG, WILLIAMS SA, MUIRHEAD DC, DEWLAND PM, TANNER T, WESNES K: Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine.Psychiatry(1996)57\(Suppl. 1):20–23.
   Google Scholar
• PINNINTI NR, DE LEON J: Interaction of sertraline with clozapine. j Clin. Psychopharmacol (1997) 17(2):199–120.
   Google Scholar
• CHONG SA, TAN CH, LEE HS: Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: two case reports. j. Clin. Psychopharmacol (1997) 17(1):68–69.
   PubMedGoogle Scholar
• PRESKORN SH, ALDERMAN J, GREENBLATT DJ, HORST WD: Sertraline does not inhibit cytochrome (P450) 3A-mediated drug metabolism in vivo. Psychopharmocal Bull. (1997) 33:659–665.
   PubMedGoogle Scholar
• CENTORRINO F, BALDESSARINI RJ, FRANKENBURG FR, KANDO J, VOLPICELLI SA, FLOOD JG: Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am. j Psychiatry(1996) 153(0820–822.
   PubMed Web of Science ®Google Scholar
• HOEHNS JD, FOUTS MM, KELLY MW, TU KB: Sudden cardiac death with clozapine and sertraline combination. Ann. Psychoparmacother. (2001) 35(7–8)862–866.
   Google Scholar
• HAMILTON SP, NUNES EV, JANAL M, WEBER L. The effect of sertraline on methadone plasma levels in methadone-maintenance patient. Am. Addict. (2000) 9:63–69.
   PubMed Web of Science ®Google Scholar
• KAUFMAN KR, GERNERR: Lamotrigine toxicity secondary to sertraline. Seizure (1998) 7:163–165.
   PubMedGoogle Scholar
• DAVIDSON JRT, LONDBORG P, PEARLSTEIN T, ROTHBAUM BO, BRADY K, FARFEL GM. Double-Blind, Randomized, 28-Week Continuation Study Of Sertraline And Placebo In Posttraumatic Stress Disorder (PTSD). Presented at the American Psychiatric Association Annual Meeting (May 13–18, 2000) Chicago, IL, USA.
   Google Scholar